AR and breast carcinoma: Moreover, it has been demonstrated that patients with breast cancer that express the androgen receptor tolerate enzalutamide well and benefit from enzalutamide treatment, suggesting enzalutamide has a significant antitumor effect and safety in AR positive breast cancer [16].